Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis

Rik J B Loymans general practitioner, Armin Gemperli assistant professor, Judith Cohen general practitioner, Sidney M Rubinstein senior researcher, Peter J Sterk professor, Helen K Reddel research leader, Peter Jüni professor, Gerben ter Riet associate professor

1Department of General Practice, Academic Medical Center, University of Amsterdam, PO box 22700, 1105 DE, Amsterdam, Netherlands; 2Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine, University of Bern, Berne, Switzerland; 3Department of Health Sciences and Health Policy, University of Lucerne, Lucerne, Switzerland; 4Swiss Paraplegic Research, Nottwil, Switzerland; 5Department of Health Sciences, Section Health Economics and Health Technology Assessment, VU University Amsterdam, Amsterdam, Netherlands; 6Department of Respiratory Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; 7Clinical Management Group, Woolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia

Abstract

Objective To determine the comparative effectiveness and safety of current maintenance strategies in preventing exacerbations of asthma.

Design Systematic review and network meta-analysis using Bayesian statistics.

Data sources Cochrane systematic reviews on chronic asthma, complemented by an updated search when appropriate.

Eligibility criteria Trials of adults with asthma randomised to maintenance treatments of at least 24 weeks duration and that reported on asthma exacerbations in full text. Low dose inhaled corticosteroid treatment was the comparator strategy. The primary effectiveness outcome was the rate of severe exacerbations. The secondary outcome was the composite of moderate or severe exacerbations. The rate of withdrawal was analysed as a safety outcome.

Results 64 trials with 59622 patient years of follow-up comparing 15 strategies and placebo were included. For prevention of severe exacerbations, combined inhaled corticosteroids and long acting β agonists as maintenance and reliever treatment and combined inhaled corticosteroids and long acting β agonists in a fixed daily dose performed equally well and were ranked first for effectiveness. The rate ratios compared with low dose inhaled corticosteroids were 0.44 (95% credible interval 0.29 to 0.66) and 0.51 (0.35 to 0.77), respectively. Other combined strategies were not superior to inhaled corticosteroids and all single drug treatments were inferior to single low dose inhaled corticosteroids. Safety was best for conventional best (guideline based) practice and combined maintenance and reliever therapy.

Conclusions Strategies with combined inhaled corticosteroids and long acting β agonists are most effective and safe in preventing severe exacerbations of asthma, although some heterogeneity was observed in this network meta-analysis of full text reports.

Introduction

Asthma is a widespread chronic airway disease characterised by an unpredictable course. Preventing exacerbations is considered a major long term treatment goal in international guidelines. These episodes of sudden deterioration of symptoms and airways obstruction result in a burden to the patient and use of expensive medical resources. Asthma related healthcare expenses in patients with exacerbations are double ($1740 (£1035; €1257) v $847) those of patients without exacerbations.

Although inhaled corticosteroids—anti-inflammatory controller drugs—are currently the cornerstone of preventing asthma exacerbations, several other agents or combination strategies...
have been investigated. Such strategies include combinations of existing agents, such as inhaled corticosteroids and long acting β agonists, and other agents, such as leukotriene receptor antagonists and anti-IgE antibodies, which have been tested in multiple clinical trials.

Previous research syntheses on the effectiveness of different strategies in asthma have been informative but have drawbacks, such as only comparing pairs of strategies, non-standardised definitions of drug dosages and outcomes, and inclusion of mainly trials with a follow-up of less than 20 weeks. Hence a more standardised comparison of all relevant drug maintenance strategies to prevent asthma exacerbations is needed. Network meta-analysis (also called multiple treatment comparison) is a relatively new approach that uses all available evidence and formally compares all existing strategies.

We determined the comparative effectiveness and safety of all available maintenance treatment strategies for chronic asthma for their ability to reduce consistently defined exacerbations during long term treatment, and to rank them for these outcomes. We carried out a network meta-analysis of drug interventions to prevent exacerbations in patients with persistent asthma, in trials of at least 24 weeks’ duration, and with exacerbations defined according to the American Thoracic Society/European Respiratory Society.

**Methods**

**Systematic review and data extraction**

To identify randomised controlled trials we assessed all Cochrane systematic reviews on chronic asthma (http://airways.cochrane.org/our-reviews) published before 1 August 2011 and selected the 16 on drug interventions in adults. We assessed all studies included in these reviews, as well as those that were listed as having been rejected by the Cochrane authors. We carried out an update search for all reviews using the identical search terms reported in these reviews. This search was performed on 1 August 2013 in the Cochrane Airways Group register of trials, which consists, among others, of trials on asthma in Medline, Embase, and the Cochrane Central Register of Controlled Trials (http://airways.cochrane.org/trials-register). We screened all references of included reports for eligible trials. Eligible reports were full text randomised controlled trials lasting at least 24 weeks that compared different drug strategies for the maintenance treatment of asthma in adults and reported on exacerbations. We applied no restrictions on language or publication date. For an intervention to be included in the analysis, it had to be evaluated in at least two separate trials. One investigator removed all reports that were not full text publications and reports on interventions lasting less than 24 weeks. Two investigators independently assessed all remaining reports on title and abstract. The full text of those remaining was assessed against the inclusion criteria. Two investigators (RL and JC) used standardised forms to independently extract data on the characteristics of publication, patients, intervention, outcomes, and risk of bias. We assessed risk of bias from selection, performance, attrition, detection, and selective reporting according to recommendations in the Cochrane handbook. Differences were resolved by agreement, after which we entered data in a database using a dedicated entry screen. To screen for publication bias we created funnel plots for all direct comparisons yielding five or more studies. We emailed the corresponding authors for missing data on outcomes. After data extraction, we evaluated studies against the similarity assumptions required for network meta-analysis—that is, the extent to which covariates, such as patient characteristics, that would act as modifiers of relative treatment effects were similar across studies. For this reason we included only full text reports: abstracts presented at conferences and from manufacturer’s websites do not contain sufficient information on patient characteristics, methods, and quality to assess whether similarity assumptions are met. Also, we omitted trials on tailored strategies with monoclonal antibodies or maintenance treatment with systemic corticosteroids, since these strategies are only used for specific patient phenotypes with severe asthma.

**Measuring treatment effect**

Given the known wide variation in definitions of asthma exacerbations in the literature, we created standardised criteria for moderate and severe exacerbations before data extraction that were consistent with American Thoracic Society/European Respiratory Society recommendations. If a report defined exacerbations as hospital admission, visit to an emergency department, or prescription of systemic corticosteroids for at least three days, we classified the events as severe exacerbations. We classified events as moderate exacerbations if they were defined by a decrease in pulmonary function (peak flow or forced expiratory volume), increased use of rescue drugs, or night time waking because of asthma symptoms (all for at least two consecutive days), or by unscheduled visits to or by a doctor. Unless the report stated that most events fulfilled the criteria for severe exacerbations, we classified events defined by elements of both severe and moderate exacerbations as moderate exacerbations.

We converted all doses of inhaled corticosteroids into dose equivalents of beclometasone by multiplying with conversion factors: 1.0 for beclometasone with chlorofluorocarbon propellant, 2.0 for beclometasone with hydrofluoroalkane propellant, 1.25 for budesonide chlorofluorocarbon, 1.25 for budesonide hydrofluoroalkane, 0.5 for fluticasone, 2.0 for fluticasone propionate, 1.5 for mometasone, and 0.5 for triamcinolone, with a threshold of 500 µg beclometasone chlorofluorocarbon a day to discriminate low doses from medium or high doses. We regarded fluticasone propionate 2.5 as equipotent to fluticasone furoate 1.0 according to the manufacturer’s summary of product characteristics.

Exacerbations in the literature, exacerbations are commonly reported as exacerbations with at least one exacerbation, or exacerbation rates (numbers per person time of follow-up). We calculated rates per trial arm from the numbers of exacerbations and patient years; the numbers of patient years were estimated by multiplying the number of patients by the intended follow-up time, assuming that patients who withdrew during the intervention had done so halfway through the trial. If numbers of exacerbations were not available, we used the reported exacerbation rates, and we distinguished between rates weighted by follow-up duration and those not weighted, since non-weighted rates tend to yield exaggerated effect estimates. If numbers of patients with exacerbations were only reported, we imputed the number of exacerbations with estimations using median regression with linear and quadratic terms of numbers of patients with exacerbations and patient years as covariates.
Measuring safety

Owing to the wide variation in reporting of adverse events, we analysed reported withdrawals as a result of adverse events as the primary safety variable. These rates were reported in most studies, varied little in definition, and were considered most likely to reflect the reasons for decisions to withdraw. As a secondary safety outcome we analysed the total number of withdrawals.

Statistical analysis

We used Bayesian hierarchical random effects models,36 fully preserving randomised treatment effects within trials and accounting for correlation between comparisons within multiarm trials.7 Adjusting for patient years under all situations, we used a log-linear Poisson model (exacerbation rate ratios) to analyse the number of exacerbations and a logistic model (odds ratios) with complementary log-log link function to analyse the numbers of patients with at least one exacerbation and the number of study withdrawals. We fitted models with Markov chain Monte Carlo simulations with non-informative priors.15 Pooled rate ratios were estimated from the median of the posterior distribution of the difference in risk estimate between two treatments and corresponding 95% credible intervals derived. For each strategy we estimated the probability of its rank order and 95% credible interval by determining the median of the posterior distribution of the difference in risk estimate between two treatments and corresponding 95% credible intervals derived. For each strategy we estimated the probability of its rank order and 95% credible interval by determining the median of the posterior distribution of the difference in risk estimate between two treatments and corresponding 95% credible intervals derived. For each strategy we estimated the probability of its rank order and 95% credible interval by determining the median of the posterior distribution of the difference in risk estimate between two treatments and corresponding 95% credible intervals derived. For each strategy we estimated the probability of its rank order and 95% credible interval by determining the median of the posterior distribution of the difference in risk estimate between two treatments and corresponding 95% credible intervals derived.

Results

From the Cochrane reviews16-32 we identified 4851 records and assessed 170 full text reports, of which 70 met our inclusion criteria (fig 1⇓). We excluded four strategies from analysis—cromoglycate,33 theophylline,34 azithromycin add-on treatment,41 and combined inhaled corticosteroids, long acting β agonists, and theophylline—42—as they were identified as a strategy in only one eligible trial. Six reports yielded data that could not be synthesised, mainly because of lack of data on exacerbations35-38 and patient years.39-41 Overall, 64 reports describing 66 trials containing 59 622 patient years were included in the analysis (also see web extra table S1).44 51-53-55 Of the 13 corresponding authors contacted, three provided additional data.

The intervention lasted approximately six months in more than half of the reports (37/64, 58%), one year in 25 (39%), and more than one year in only two.

Classification of treatment strategies

A total of 16 interventions were analysed (table I and fig 2⇓): regular short or long acting β agonists; leukotriene receptor antagonists; and low dose inhaled corticosteroids (the reference strategy) or high dose inhaled corticosteroids separately or combined with regular short or long acting β agonists or with leukotriene receptor antagonists. For combination therapy (combined inhaled corticosteroids and long acting β agonists in a single inhaler), we identified four strategies: combined fixed dose treatment with low or high steroid doses and short acting β agonists as reliever; combined adjustable maintenance dose and short acting β agonists as reliever, in which maintenance therapy was adjusted by either the doctor or the patient; and combined maintenance and reliever therapy, in which the combined inhaler was prescribed for both fixed maintenance dosing and “as needed” reliever. Some studies compared the index intervention with placebo, others to current guidelines (best practice). Some minor treatment variations were included: combined fixed dose treatment with as needed long acting β agonists69 was included in combined fixed dose treatment, and combined fixed dose treatment plus additional maintenance inhaled corticosteroids with as needed short acting β agonists67 was included in combined fixed dose treatment with high dose steroids.

Risk of bias

Poor reporting hampered complete assessment of risk of bias, with 179/448 (40%) of the items classified as unclear (see web extra table S2). In about 30% of the trials the risk of selection bias (sequence generation and allocation concealment) was deemed to be low. Twenty two per cent (14/64) of the trials were deemed to be at high risk of bias because of problems with blinding. To deal with this we performed an additional sensitivity analysis. Incomplete outcomes were tackled relatively well, with approximately 80% assessed as being at low risk of bias. Although after 2005 most trials were registered, they were not all assessed as being at low risk of selective outcome reporting, as some trials were registered retrospectively or outcome variables were not registered before the start of the trial. All reports except two66 107 were linked with the pharmaceutical industry through authorship (52/64), sponsorship or funding (56/64), or both (45/64). Funnel plots of all direct comparisons with five or more studies did not show clear evidence of small study bias (see web extra figure S3), although assessment was hampered by sparse data: no direct comparisons concerned 10 or more studies.

Severe exacerbations

We analysed 57 trials, including 53 309 patient years, for severe exacerbations. Low dose inhaled corticosteroids (the reference strategy) were superior to all other single agent strategies in preventing severe exacerbations (fig 3⇓). The rate ratio for placebo compared with low dose inhaled corticosteroids was 4.19 (95% credible interval 2.87 to 6.16). For preventing severe exacerbations, only combined maintenance and reliever treatment and combined fixed dose treatment performed significantly better than all other single agent strategies.
significantly better than low dose inhaled corticosteroids, with rate ratios of 0.44 (0.29 to 0.66) for combined maintenance and reliever treatment and 0.51 (0.35 to 0.77) for combined fixed dose treatment (fig 3). All other treatment strategies that used combined inhaled corticosteroids and another agent, whether by single or separate inhalers, tended to perform better than low dose inhaled corticosteroids, although the difference was not statistically significant. Data for exacerbation rates without imputation were available for 45 trials (see web extra figure S1); results were largely similar to the primary analysis, although in severe exacerbations the difference between the common comparator and combined fixed dose treatment was no longer significant (0.63, 0.40 to 1.02). Figure 3 also shows the estimated ranks of effectiveness for all strategies, with associated 95% credible intervals. The rankograms (fig 4) show the probability of the effectiveness of each strategy, ordered from the highest rank (combined maintenance and reliever treatment and combined fixed dose treatment) to the lowest rank (placebo). We carried out preplanned stratified analyses based on risk of bias assessment, study duration, study size, and presstudy treatment step1 (see web extra figures S2 A-D), and additional sensitivity analyses excluding studies that reported non-weighted exacerbation rates (web extra figure S2 E) and unblinded studies (web extra figure S2 F). These analyses did not show clear differences from the primary analysis; eight out of 17 trials that studied combined maintenance and reliever treatment (containing 2656/8174 patient years) were excluded in this sensitivity analysis, but similar rate ratios and rank orders were observed. Some of the sensitivity analyses (for example, in studies of more than 30 weeks’ duration) were hampered by small numbers of events, resulting in wide credible intervals. The estimate of between study variance (heterogeneity) was moderate; $\tau^2=0.102$. For five out of 31 comparisons (inhaled corticosteroids versus inhaled corticosteroids and long acting $\beta$ agonists, inhaled corticosteroids versus combined maintenance and reliever treatment, inhaled corticosteroids and regular short acting $\beta$ agonists versus regular short acting $\beta$ agonists, combined fixed dose treatment versus combined maintenance and reliever treatment, and regular long acting $\beta$ agonists versus regular short acting beta agonists) we found statistical evidence for inconsistency between direct and indirect comparisons (fig 5), predominantly in direct comparisons including only one or two studies.

**Composite of moderate or severe exacerbations**

For the composite of moderate or severe exacerbations, we analysed 61 trials including 39 237 patient years (fig 3). Although point estimates for rate ratios differed from those for severe exacerbations, and credible limits were narrower—for example, combined maintenance and reliever treatment 0.54 (95% credible interval 0.42 to 0.69) and combined fixed dose treatment 0.68 (0.54 to 0.85)—overall trends were similar. Figure 4 shows rankograms for the composite of moderate or severe exacerbations, with combined maintenance and reliever treatment ranking highest. Heterogeneity was low; $\tau^2=0.070$. For two out of 33 comparisons (inhaled corticosteroids versus high dose inhaled corticosteroids with regular long acting $\beta$ agonists and high dose inhaled corticosteroids with regular long acting $\beta$ agonists versus combined maintenance and reliever treatment, we found statistical evidence for inconsistency between direct and indirect comparisons (fig 6)).

**Safety outcomes**

Figure 7 shows the risk ratios and the probability based rank order with corresponding 95% credible intervals for withdrawal as a result of adverse events for each strategy. Best practice had the lowest rate of withdrawals due to adverse events. Combined maintenance and reliever treatment was also associated with significantly fewer withdrawals because of adverse events compared with low dose inhaled corticosteroids. There was little variation in withdrawal rates between the other treatment strategies and no statistically significant differences from the reference strategy. These results were largely confirmed by total number of withdrawals (fig 7). (See web extra table S3 for reported harms.)

**Discussion**

The purpose of this systematic review and network meta-analysis was to identify all commonly used strategies for the prevention of exacerbations of chronic asthma, estimate their efficacy and safety compared with low dose inhaled corticosteroids, and order them by rank. Our primary analysis shows that both combined inhaled corticosteroids and long acting $\beta$ agonists as maintenance and reliever treatment and combined inhaled corticosteroids and long acting $\beta$ agonists as fixed dose treatment significantly reduced the risk of severe exacerbations compared with low dose inhaled corticosteroids alone, with the combination strategies having similar rate ratios and a similar ranking in the probability analysis. Other strategies that included more than one agent performed similarly to each other compared with low dose inhaled corticosteroids, and were not statistically worse than combined maintenance and reliever treatment or combined fixed dose treatment. All combined strategies outperformed single agent strategies of regular leukotriene receptor antagonists or long acting $\beta$ agonists. When the total exacerbation burden was considered, using studies that reported both moderate and severe exacerbations, combined maintenance and reliever treatment ranked highest, approximately halving the risk of exacerbations compared with low dose inhaled corticosteroids. These results provide an overview of efficacy of all common treatment regimens in the prophylaxis of asthma exacerbations, which can be used as a starting point in clinical practice.

**Comparison with other studies**

Our approach is novel in that it includes all published treatment options in a single analysis, allowing quantitative ranking of all the available evidence. Our findings confirm and extend previous focused studies based on direct pairwise comparisons of treatments. Two meta-analyses, a Cochrane review25 and an industry sponsored analysis,26 favoured combined maintenance and reliever treatment over specific comparators in reducing severe exacerbations, including combined fixed dose treatment. In the more extensive analysis of the present study, apart from combined maintenance and reliever treatment and combined fixed dose treatment, treatment strategies involving an inhaled corticosteroid and another agent, whether in one device or two devices, did not perform statistically significantly better than our reference strategy, low dose inhaled corticosteroids. The combined strategies performed equally well in preventing severe exacerbations, an observation challenging a previous meta-analysis of six studies, four of which were of 4-12 weeks’ duration.22 The meta-analysis concluded that the addition of long acting $\beta$ agonists to inhaled corticosteroids was favoured over the addition of leukotriene receptor antagonists. In our network meta-analysis, in which inhaled corticosteroid doses...
were classified as either low or moderate or high, we were unable to confirm the previously reported positive effects of increasing doses of inhaled corticosteroids in preventing exacerbations.11 This is probably because in the included studies the intervention of inhaled corticosteroid dose was typically double that of the control inhaled corticosteroid dose, but both doses may still have fallen within either our low dose or moderate or high dose inhaled corticosteroid categories. Another explanation may be underlying differences in the original patient populations. For example, there were differences in baseline forced expiratory volume in one second (%) predicted between patients in trials using high dose inhaled corticosteroids (median 72.2%, range 64.0-95.5%), interquartile range 69.0-75.4%) and those using low dose inhaled corticosteroids (median 82.3%, range 65.6-102.0%, interquartile range 75.4-88.8%). For severe exacerbations as well as the composite of moderate or severe exacerbations, low dose inhaled corticosteroids seemed to be superior to regular short or long acting β agonists or to leukotriene receptor antagonists alone, a finding that has been observed previously.19 21

Strengths and limitations of this study

Our study has several strengths. Firstly, network meta-analysis allowed comparison of all available strategies in a single analysis, giving a combined total of 59 622 patient years of treatment, rather than separate and disconnected meta-analyses for individual pairs of treatments. By conducting a network meta-analysis we were able to provide a formal rank order for treatment strategies by their capacity to reduce exacerbations, while capturing the imprecision of such rankings. Secondly, we carefully developed the inclusion criteria for trials. As exacerbations are relatively infrequent outcomes, we restricted our study to reports with treatment durations of at least 24 weeks (close to six months) to reflect the effects of long term treatment in a variable disease. In several other meta-analyses with exacerbations as an outcome variable, the bulk of the evidence has originated from studies with durations of intervention between three and six months, a relatively short period as asthma treatment usually lasts for years, and in clinical trials the effects of treatment seem to decrease with increasing duration of intervention.13 17 22 24

Thirdly, where the interpretation of previous reviews was hampered by pooling of data based on variously defined exacerbations, we applied predetermined standardised definitions based on those of the American Thoracic Society/European Respiratory Society.17 This allowed a comprehensive cross comparison of all studies. As recommended by the report of the American Thoracic Society/European Respiratory Society, we did not attempt to classify mild exacerbations. The composite of moderate or severe exacerbations combined can thus be regarded for clinical interpretation as representing the total number of exacerbations. Thirty nine studies measured severe exacerbations, but only 17 were consistent with this current definition. In addition, we found that exacerbation outcomes, particularly for severe exacerbations, were reported in several ways (number of exacerbations, number of patients with at least one exacerbation, and weighted or non-weighted exacerbation rates annually or in other time frames), underscoring the value of our recalculations to reliably compare strategies. We acknowledge the following limitations to our work. Firstly, the criteria for selection of strategies was based on existing Cochrane reviews and our own searches to update those reviews, so the comprehensiveness of our study depends on the adequacy of the original Cochrane research questions and search terms. Secondly, we did not include unpublished or premarketing studies from drug regulatory agencies such as the Food and Drug Administration and European Medicines Agency; this might have led to a reporting bias.10 However, since all included studies were related to the pharmaceutical industry, differential reporting bias may have been reduced.11 Thirdly, there was heterogeneity between trial populations—for example, in baseline lung function. This might explain some of the observed inconsistency and heterogeneity for the primary outcome of severe exacerbations. If this were the case, we would expect the same pattern in the analysis of the secondary composite outcome of moderate or severe exacerbations. However, this analysis yielded low heterogeneity and little evidence for inconsistency. Moreover, inconsistencies were nearly exclusively observed in direct comparisons with only one or two trials. Therefore believe that the patients included in our component trials were sufficiently similar to meet the similarity assumptions for network meta-analysis. Finally, the generalisability of the findings is limited by the original trial inclusion criteria—for example, many studies required non-smokers with significant bronchodilator reversibility, so participants were not necessarily representative of the general population with asthma.112 However, a requirement for an exacerbation in the previous 12 months, seen in more recent studies, is not regarded as a limitation if the aim of the study was to reduce exacerbations.

Policy implications

Low dose inhaled corticosteroids are highly effective in reducing severe asthma exacerbations, with patients receiving placebo having a rate ratio of over 4 for experiencing a severe exacerbation within six months. In comparison with low dose inhaled corticosteroids, we identified combined maintenance and reliever treatment as the highest ranked strategy for preventing total exacerbations (composite of moderate or severe), and equally ranked with combined fixed dose treatment for preventing severe exacerbations. It has been proposed that the mechanism for greater reduction of exacerbations with the combined maintenance and reliever treatment strategy is from either an early (patient initiated) up-titration of inhaled corticosteroids and β agonist dose as soon as asthma symptoms worsen, thus avoiding delays by doctors or patients, or greater adherence with drugs containing inhaled corticosteroids. Both of these ideas was supported by one of the included studies, independent of pharmaceutical companies, using real time electronic monitoring of all inhalers supports.107 Although some of the studies of combined maintenance and reliever treatment included in the present analysis were unblinded, a sensitivity analysis omitting unblinded trials (eight trials with 2656 patient years of the combined maintenance and reliever treatment strategy), showed similar results to the primary analysis. All strategies consisting of inhaled corticosteroids together with another agent had rate ratios below 1, suggesting better performance than inhaled corticosteroids used alone, although none of these differences, other than combined maintenance and reliever treatment and combined fixed dose treatment, were statistically significant for severe exacerbations. This does not, however, allow the conclusion that these two strategies are statistically better than other combination strategies. Not unexpectedly, the rank numbers of these inhaled corticosteroids combined with other agent strategies have broad credible intervals and therefore may be regarded as equally effective in preventing exacerbations. Therefore, a choice of any treatment containing inhaled corticosteroids should be based on other factors, such as impact on control of asthma symptoms,113 patient or doctor preference, cost, availability, or potential for side
effects. Monotherapy with agents other than inhaled corticosteroids was not as effective in preventing exacerbations. Subsequent network meta-analysis may show whether this also holds for outcomes such as symptoms, lung function, and cost, although the heterogeneity between studies in reporting of such outcomes is even more noticeable than for exacerbations, and there is increasing recognition of discordance between current asthma control and adverse outcomes such as exacerbations.17

In terms of safety, it was not surprising that the best practice strategy had the lowest withdrawal rate. This intervention, in which the patient and practitioner are free to choose the drug or regimen that they believe is superior or safer than others, is only possible in open label trials. In an open label study, both patients and practitioners are less likely to withdraw from a familiar treatment (best practice) than from an unfamiliar (new) treatment. In contrast with best practice, all other interventions (including combined maintenance and reliever treatment and combined fixed dose treatment) were found in both open label and double blind trials. Withdrawal rates are typically higher in double blind trials. Combined maintenance and reliever treatment ranked second only to current best practice in the safety measures. For other strategies, withdrawals as a result of adverse events were not significantly different from those of low dose inhaled corticosteroids; total numbers of withdrawals were significantly higher with placebo and with long acting β agonists compared with low dose inhaled corticosteroids.

Conclusions

This comprehensive network meta-analysis shows that combined inhaled corticosteroids and long acting β agonists as maintenance and reliever treatment has a good safety profile and is better in preventing total asthma exacerbations than low dose inhaled corticosteroids alone. Treatment with a combined fixed dose was equally effective at reducing severe exacerbations. All combinations of inhaled corticosteroids and other agents seem to be similarly effective and not significantly better than low dose inhaled corticosteroids. These results suggest that, when low dose inhaled corticosteroids are not sufficiently effective, combined maintenance and reliever treatment or combined fixed dose treatment may be preferred for the reduction of exacerbations.

We thank Farid van Etten-Jamaladin, clinical librarian, and René Spiker, clinical librarian and trial search coordinator of the Dutch Cochrane Collaboration at the Academic Medical Center for their assistance with the search strategy; and Chris Cates, coordinating editor, and Elizabeth Stovold, trial search coordinator of the Cochrane Airways Group for making the Cochrane Airways Group Register of Trials accessible and conducting the searches.

This study was registered in the PROSPERO database as CRD42012001999 (www.crd.york.ac.uk/PROSPERO).

Contributors: GiR and RJBL conceived the study. RJBL, GiR, SMR, HKR, JC, PJS, PJ, and AG contributed to the study protocol. RJBL and JC selected reports and extracted the data. RJBL, AG, GiR, and PJ analysed and interpreted the data. RJBL and GiR wrote the first draft of the manuscript. All authors critically revised the manuscript for intellectual content and approved the final version. They had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. RJBL and GiR act as guarantors.

Funding: This investigator initiated study was not supported by any industrial or public funding.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; HKR has participated on advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Novartis, is participating on a joint data monitoring committee for AstraZeneca, GlaxoSmithKline, Merck, and Novartis, has provided consultancy services for AstraZeneca, GlaxoSmithKline, and Mundipharma, has provided continuing medical education presentations at symposiums funded by AstraZeneca, Boehringer Ingelheim, Getz, GlaxoSmithKline, and Merck, and has received unconditional research funding from AstraZeneca and GlaxoSmithKline. PJ is an unpaid member of steering groups or executive committees of trials funded by Abbott Vascular, Biosensors, Medtronic, and St Jude Medical. CTU Bern, which is part of the University of Bern, has a staff policy of not accepting individual honorariums or consultancy fees. However, CTU Bern is involved in the design, conduct, or analysis of clinical studies funded by Abbott Vascular, Abylun, Amgen, AstraZeneca, Biosensors, Biontronic, Boehringer Ingelheim, Eisai, Eli Lilly, Exelixis, Geron, Gilead Sciences, Nestlé, Novartis, Novo Nordisk, Padma, Roche, Schering-Plough, St Jude Medical, and Swiss Cardio Technologies; there are no non-financial interests that may be relevant to the submitted work.

Ethical approval: Not required.

Data sharing: Dataset and statistical code are available from the corresponding author at r.j.loijmans@amc.nl.

Transparency: The lead author (the manuscript’s guarantor), affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

7 O’Byrne PM. Therapeutic strategies to reduce asthma exacerbations. J Allergy Clin Immunol 2011;128:257-63.
13 Sin DD, Man J, Sharpo H, Gan WQ, Man SF. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 2004;292:367-76.
What is already known on this topic

Adding long-acting β agonists to asthma treatment is preferred to raising the dose of inhaled corticosteroids to prevent exacerbations.

Several meta-analyses have assessed other treatment strategies, such as leukotriene antagonists and single inhaled combination devices.

What this study adds

Combined inhaled corticosteroids and long-acting β agonists as maintenance and reliever treatment or in a fixed daily dose are the only treatment options better than low dose inhaled corticosteroids in preventing total asthma exacerbations.

These two strategies seem preferred when low dose inhaled corticosteroids are not sufficient, and step-up of treatment is warranted.


Accepted: 14 April 2014

Cite this as: BMJ/2014/348:g3009

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
## Table

Table 1 | Identified strategies for maintenance treatment of asthma

<table>
<thead>
<tr>
<th>Strategy and generic name</th>
<th>Daily dose (µg)</th>
<th>Medium/high dose ICS strategy</th>
<th>Daily dose (µg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SABA:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salbutamol</td>
<td>NS</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Terbutaline</td>
<td>NS</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>LABA*:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol</td>
<td>NS</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Salmeterol</td>
<td>NS</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>LTRA*:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Montelukast</td>
<td>12</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>ICS*:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beclomethasone</td>
<td>200-500</td>
<td>ICS H*</td>
<td>&gt;500</td>
</tr>
<tr>
<td>Budesonide</td>
<td>200-400</td>
<td>ICS H*</td>
<td>&gt;400</td>
</tr>
<tr>
<td>Fluticasone</td>
<td>100-250</td>
<td>ICS H*</td>
<td>&gt;250</td>
</tr>
<tr>
<td>Ciclesonide</td>
<td>80-160</td>
<td>ICS H*</td>
<td>&gt;160</td>
</tr>
<tr>
<td>Mometasone</td>
<td>200-400</td>
<td>ICS H*</td>
<td>&gt;400</td>
</tr>
<tr>
<td>ICS+SABA*</td>
<td></td>
<td>Combined as above, in separate inhalers</td>
<td></td>
</tr>
<tr>
<td>ICS H+SABA*</td>
<td></td>
<td>Combined as above, in separate inhalers</td>
<td></td>
</tr>
<tr>
<td>ICS+LABA*</td>
<td></td>
<td>Combined as above, in separate inhalers</td>
<td></td>
</tr>
<tr>
<td>ICS+LTRA*</td>
<td></td>
<td>Combined as above, in separate inhalers</td>
<td></td>
</tr>
<tr>
<td>COMBI FIX*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beclomethasone/formoterol</td>
<td>100/6-200/12</td>
<td>COMBI FIX H*</td>
<td>&gt;200/12</td>
</tr>
<tr>
<td>Budesonide/formoterol</td>
<td>200/6-400/12</td>
<td>COMBI FIX H*</td>
<td>&gt;400/12</td>
</tr>
<tr>
<td>Fluticasone/salmeterol</td>
<td>250/50</td>
<td>COMBI FIX H*</td>
<td>&gt;250/50</td>
</tr>
<tr>
<td>Mometasone/formoterol</td>
<td>100/5-300/20</td>
<td>COMBI FIX H*</td>
<td>&gt;400/20</td>
</tr>
<tr>
<td>COMBI AMD*</td>
<td></td>
<td>As COMBI FIX, but dose regularly adapted by doctor or patient, guided by symptoms</td>
<td></td>
</tr>
<tr>
<td>COMBI MAR</td>
<td></td>
<td>As COMBI FIX, but combination agent also used as relief or rescue agent when warranted</td>
<td></td>
</tr>
<tr>
<td>Best Practice</td>
<td></td>
<td>Doctors requested to treat patients according to current or local asthma treatment guidelines</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td>Non-active comparator</td>
<td></td>
</tr>
</tbody>
</table>

ICS=inhaled corticosteroids; SABA=short acting β agonists, regular use; NS=not specified; LABA=long acting β agonists, regular use; LTRA=leukotrien receptor antagonist; H=high daily dose inhaled corticosteroids (>500 µg beclomethasone equivalents); COMBI=combined ICS and LABA in single inhaler; COMBI FIX=COMBI in fixed daily dose; COMBI AMD=COMBI in adjustable maintenance dose; COMBI MAR=COMBI as maintenance and reliever treatment.

ICS doses by approximation, for analysis dose equivalents of beclomethasone was used as stated in methods section.

*Relief or rescue drug with short acting β agonists allowed.
Figures

Fig 1 Flow chart of study selection
Fig 2 Overview of treatment strategies, with lines representing direct (head to head) comparisons; surface areas of circles proportional to number of patients identified in strategy. Numbers in lines are number of direct comparisons. COMBI=combined inhaled corticosteroid (ICS) and long acting β agonist (LABA) in single inhaler; COMBI MAR=COMBI as maintenance and reliever treatment; COMBI FIX=COMBI in fixed daily dose; COMBI AMD=COMBI in adjustable maintenance dose; H=high dose; LABA=long acting β agonists, regular use; LTRA=leukotriene receptor antagonist; SABA=short acting β agonists, regular use
Fig 3 Forest plot showing asthma exacerbation rate ratios and median ranks with corresponding 95% credible intervals for each strategy compared with low dose inhaled corticosteroids (ICS). COMBI=combined ICS and long acting β agonist (LABA) in single inhaler; COMBI MAR=COMBI as maintenance and reliever treatment; COMBI FIX=COMBI in fixed daily dose; COMBI AMD=COMBI in adjustable maintenance dose; H=high dose; LABA=long acting β agonists, regular use; LTRA=leukotriene receptor antagonist; SABA=short acting β agonists, regular use.
Fig 4 Rankograms showing probability (percentage) of each strategy having each specific rank (1-16) for effectiveness in the prevention of severe and composite of moderate or severe asthma exacerbations. Strategies ordered by rank from top left to bottom right. In severe exacerbations, combined inhaled corticosteroids (ICS) and long acting β agonists (LABA) in single inhaler as maintenance and reliever treatment (COMBI MAR), and in fixed daily dose (COMBI FIX) have highest probabilities to be ranked first and placebo the highest probability to be ranked last. COMBI AMD=combined ICS and LABA in adjustable maintenance dose; H=high dose; LTRA=leukotriene receptor antagonist; SABA=short acting β agonists, regular use.
Fig 5 Difference in estimated treatment effects for severe asthma exacerbations between direct comparison (based on classic meta-analysis) and indirect estimate from multi-treatment comparison (without respective direct comparison). Difference on log-relative risk scale for rates; variance constructed by adding up variances of both estimates. Best practice is an open label comparator in which practitioners are encouraged to treat patients according to current treatment guidelines. COMBI=combined ICS and long acting β agonist (LABA) in single inhaler; COMBI MAR=COMBI as maintenance and reliever treatment; COMBI FIX=COMBI in fixed daily dose; COMBI AMD=COMBI in adjustable maintenance dose; H=high dose; LABA=long acting β agonists, regular use; LTRA=leukotriene receptor antagonist; SABA=short acting β agonists, regular use.

<table>
<thead>
<tr>
<th>Treatment 1</th>
<th>Treatment 2</th>
<th>No</th>
<th>Difference (95% CrI)</th>
<th>Difference (95% CrI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICS</td>
<td>ICS + LABA</td>
<td>1</td>
<td>-1.08 (-2.07 to -0.08)</td>
<td>-0.57 (-1.77 to 0.63)</td>
</tr>
<tr>
<td>ICS</td>
<td>ICS + SABA</td>
<td>1</td>
<td>-0.01 (-1.22 to 1.19)</td>
<td>1.53 (-3.04 to -0.03)</td>
</tr>
<tr>
<td>ICS</td>
<td>COMBI FIX</td>
<td>6</td>
<td>0.29 (-1.08 to 1.66)</td>
<td>0.33 (-0.86 to 1.52)</td>
</tr>
<tr>
<td>ICS</td>
<td>LABA</td>
<td>3</td>
<td>-0.31 (-1.35 to 0.72)</td>
<td>-0.29 (-1.19 to 0.60)</td>
</tr>
<tr>
<td>ICS</td>
<td>LTRA</td>
<td>2</td>
<td>0.33 (-0.86 to 1.52)</td>
<td>-0.55 (-1.91 to 0.82)</td>
</tr>
<tr>
<td>ICS</td>
<td>Placebo</td>
<td>6</td>
<td>0.59 (-1.71 to 2.90)</td>
<td>0.46 (-0.80 to 1.72)</td>
</tr>
<tr>
<td>ICS H</td>
<td>ICS + LABA</td>
<td>2</td>
<td>-0.30 (-2.21 to 1.61)</td>
<td>-0.47 (-1.07 to 0.13)</td>
</tr>
<tr>
<td>ICS H</td>
<td>ICS H + LABA</td>
<td>6</td>
<td>0.18 (-0.77 to 1.13)</td>
<td>-0.21 (-1.29 to 0.87)</td>
</tr>
<tr>
<td>ICS H</td>
<td>ICS H + SABA</td>
<td>2</td>
<td>1.26 (-1.11 to 3.62)</td>
<td>1.01 (-0.81 to 2.84)</td>
</tr>
<tr>
<td>ICS H</td>
<td>COMBI FIX</td>
<td>2</td>
<td>0.05 (-0.72 to 0.81)</td>
<td>-0.07 (-0.91 to 0.76)</td>
</tr>
<tr>
<td>ICS H</td>
<td>COMBI MAR</td>
<td>1</td>
<td>0.18 (-0.77 to 1.13)</td>
<td>-0.12 (-1.29 to 0.87)</td>
</tr>
<tr>
<td>ICS H</td>
<td>LTRA</td>
<td>3</td>
<td>1.61 (0.11 to 3.12)</td>
<td>0.83 (-0.62 to 2.29)</td>
</tr>
<tr>
<td>ICS H + LABA</td>
<td>ICS H + SABA</td>
<td>2</td>
<td>-0.61 (-2.14 to 0.91)</td>
<td>-0.27 (-0.91 to 0.76)</td>
</tr>
<tr>
<td>ICS H + LABA</td>
<td>COMBI FIX</td>
<td>2</td>
<td>1.49 (-2.20 to 0.78)</td>
<td>-0.27 (-0.91 to 0.76)</td>
</tr>
<tr>
<td>ICS H + LABA</td>
<td>COMBI FIX H</td>
<td>1</td>
<td>0.83 (-0.62 to 2.29)</td>
<td>1.02 (-0.05 to 2.09)</td>
</tr>
<tr>
<td>ICS H + LABA</td>
<td>COMBI MAR</td>
<td>5</td>
<td>1.43 (0.01 to 2.85)</td>
<td>-0.34 (-1.44 to 0.77)</td>
</tr>
<tr>
<td>ICS + SABA</td>
<td>LABA</td>
<td>1</td>
<td>1.43 (0.01 to 2.85)</td>
<td>1.43 (0.01 to 2.85)</td>
</tr>
<tr>
<td>COMBI FIX</td>
<td>Placebo</td>
<td>4</td>
<td>-0.28 (-1.33 to 0.77)</td>
<td>-0.28 (-1.33 to 0.77)</td>
</tr>
</tbody>
</table>
**Fig 6** Difference in estimated treatment effect for composite of moderate or severe asthma exacerbations between direct comparison (based on classic meta-analysis) and indirect estimate from multi-treatment comparison (without respective direct comparison). Difference on log-relative risk scale for rates; variance constructed by adding up variances of both estimates. Best practice is an open label comparator in which practitioners are encouraged to treat patients according to current treatment guidelines. COMBI=combined ICS and long acting β agonist (LABA) in single inhaler; COMBI MAR=COMBI as maintenance and reliever treatment; COMBI FIX=COMBI in fixed daily dose; COMBI AMD=COMBI in adjustable maintenance dose; H=high dose; LABA=long acting β agonists, regular use; LTRA=leukotriene receptor antagonist; SABA=short acting β agonists, regular use.
Fig 7 Forest plot showing withdrawals as a result of adverse events and total number of withdrawals compared with low dose inhaled corticosteroids (ICS). Best practice is an open label comparator in which practitioners are encouraged to treat patients according to current treatment guidelines. COMBI=combined ICS and long acting β agonist (LABA) in single inhaler; COMBI MAR=COMBI as maintenance and reliever treatment; COMBI FIX=COMBI in fixed daily dose; COMBI AMD=COMBI in adjustable maintenance dose; H=high dose; LABA=long acting β agonists, regular use; LTRA=leukotriene receptor antagonist; SABA=short acting β agonists, regular use.